Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.86% $2.35
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 193.06 mill |
EPS: | -3.31 |
P/E: | -0.710 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 82.15 mill |
Avg Daily Volume: | 1.807 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.710 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.12x |
Company: PE -0.710 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.13 - 2.57 ( +/- 9.19%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-25 | Orbimed Advisors Llc | Buy | 1 841 100 | Common Stock |
2024-01-25 | Orbimed Advisors Llc | Buy | 1 041 700 | Common Stock |
2024-01-25 | Orbimed Advisors Llc | Buy | 242 200 | Common Stock |
2024-01-25 | Gordon Carl L | Buy | 1 841 100 | Common Stock |
2024-01-25 | Gordon Carl L | Buy | 1 041 700 | Common Stock |
INSIDER POWER |
---|
57.95 |
Last 100 transactions |
Buy: 13 014 935 | Sell: 4 163 691 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.35 (0.86% ) |
Volume | 0.497 mill |
Avg. Vol. | 1.807 mill |
% of Avg. Vol | 27.50 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $3.39 | N/A | Active |
---|
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.